Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGkappa monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.
Purity:
>99.0%
CAS Number:
[1792181-33-9]
Target:
IL Receptor/Related
* VAT and and shipping costs not included. Errors and price changes excepted